ETA2024 Poster Presentations Basic thyroid cancer research-1 (10 abstracts)
Effects of crizotinib in strn-alk anaplastic thyroid cancer in primary culture in vitro
Silvia Martina Ferrari 1 , Francesca Ragusa 2 , Giusy Elia 2 , Valeria Mazzi 2 , Eugenia Balestri 2 , Chiara Botrini 2 , Licia Rugani 2 , Armando Patrizio 3 , Simona Piaggi 4 , Concettina La Motta 5 , Salvatore Ulisse 6 , Camilla Virili 7 , Alessandro Antonelli 2 & Poupak Fallahi 4
1University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy; 2University of Pisa, Department of Surgical, Medical, Molecular Pathology and Critical Area, Pisa, Italy; 3Azienda Ospedaliero-Universitaria Pisana, Department of Emergency Medicine, Pisa, Italy; 4University of Pisa, Department of Translational Research and New Technologies in Medicine and Surgery, Pisa, Italy; 5Department of Pharmacy, University of Pisa, Pisa, Italy; 6University La Sapienza, Rome, "Sapienza" University of Rome, Department of Surgery, Roma, Italy; 7Sapienza, University of Rome, Department of Medico-Surgical Sciences and Biotechnologies, Medico-Surgical Sciences and Biotechnologies, Latina, Italy
Anaplastic thyroid cancer (ATC) is one of the aggressive and fatal human cancers, and accounts for <2% of thyroid carcinomas. Anaplastic lymphoma kinase (ALK) rearrangements are associated with tumor growth and considered a target for the treatment of ATC. Crizotinib is an oral small-molecule tyrosine kinase inhibitor of ALK, MET, and ROS1 kinases, approved in ALK-positive non-small cell lung cancer. The effect of crizotinib in primary human ATC (pATC) cells in transforming striatin (STRN)-ALK fusion has not yet been demonstrated in the literature. The aim of this study is to obtain pATC with STRN-ALK in vitro and investigate the antineoplastic effect of crizotinib. We obtained thyroid surgical samples from 12 ATC patients and 6 controls who were undergone to parathyroidectomy: 10/12 with pATC, 2 with transforming STRN-ALK fusion (17%). In 3/10 pATC (2 with/one without STRN-ALK), overall in those with STRN-ALK, crizotinib was able to inhibit proliferation, migration, invasion, while increased apoptosis. In addition, crizotinib was also significantly able to inhibit the proliferation of AF cells, a continuous cell line obtained by primary ATC cells. Finally, results obtained from these preclinical studies in human pATC (with STRN-ALK) in vitro will help to better understand the anticancer activity in ATC and pave the way to future clinical evaluations in these patients.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more